Literature DB >> 28459327

AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.

Anil Vachani1, Lecia V Sequist2, Avrum Spira3.   

Abstract

The past century has witnessed a transformative shift in lung cancer from a rare reportable disease to the leading cause of cancer death among men and women worldwide. This historic shift reflects the increase in tobacco consumption worldwide, spurring public health efforts over the past several decades directed at tobacco cessation and control. Although most lung cancers are still diagnosed at a late stage, there have been significant advances in screening high-risk smokers, diagnostic modalities, and chemopreventive approaches. Improvements in surgery and radiation are advancing our ability to manage early-stage disease, particularly among patients considered unfit for traditional open resection. Arguably, the most dramatic progress has occurred on the therapeutic side, with the development of targeted and immune-based therapy over the past decade. This article reviews the major shifts in the lung cancer landscape over the past 100 years. Although many ongoing clinical challenges remain, this review will also highlight emerging molecular and imaging-based approaches that represent opportunities to transform the prevention, early detection, and treatment of lung cancer in the years ahead.

Entities:  

Mesh:

Year:  2017        PMID: 28459327      PMCID: PMC5439022          DOI: 10.1164/rccm.201702-0433CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  100 in total

1.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

2.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

3.  Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

Authors:  Daniel D Karp; Sandra J Lee; Steven M Keller; Gail Shaw Wright; Seena Aisner; Steven Alan Belinsky; David H Johnson; Michael R Johnston; Gary Goodman; Gerald Clamon; Gordon Okawara; Randolph Marks; Eric Frechette; Worta McCaskill-Stevens; Scott M Lippman; John Ruckdeschel; Fadlo R Khuri
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

4.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

5.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.

Authors:  N van Zandwijk; O Dalesio; U Pastorino; N de Vries; H van Tinteren
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

6.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:  Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2015-12-19       Impact factor: 41.316

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

View more
  31 in total

1.  Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis.

Authors:  Chimbu Chinniah; Louise Aguarin; Phillip Cheng; Cristina Decesaris; Alicia Cutillo; Abigail T Berman; Melissa Frick; Abigail Doucette; Keith A Cengel; William Levin; Stephen Hahn; Jay F Dorsey; Charles B Simone; Gary D Kao
Journal:  Clin Lung Cancer       Date:  2019-05-04       Impact factor: 4.785

Review 2.  Physiologic and psychologic adaptation to exercise interventions in lung cancer patients undergoing chemotherapy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Junga Lee
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.603

Review 3.  Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.

Authors:  Heidi A Hamann; Elizabeth S Ver Hoeve; Lisa Carter-Harris; Jamie L Studts; Jamie S Ostroff
Journal:  J Thorac Oncol       Date:  2018-05-23       Impact factor: 15.609

4.  Association of Leisure-Time Physical Activity With Health-Related Quality of Life Among US Lung Cancer Survivors.

Authors:  Duc M Ha; Allan V Prochazka; David B Bekelman; Jennifer E Stevens-Lapsley; Edward D Chan; Robert L Keith
Journal:  JNCI Cancer Spectr       Date:  2021-01-23

5.  Heart rate variability and heart rate recovery in lung cancer survivors eligible for long-term cure.

Authors:  Duc Ha; Atul Malhotra; Andrew L Ries; Wesley T O'Neal; Mark M Fuster
Journal:  Respir Physiol Neurobiol       Date:  2019-07-31       Impact factor: 1.931

6.  Risk factors and mortality of adults with lung cancer admitted to the intensive care unit.

Authors:  Chih-Cheng Lai; Chung-Han Ho; Chin-Ming Chen; Shyh-Ren Chiang; Chien-Ming Chao; Wei-Lun Liu; Jhi-Joung Wang; Ching-Chieh Yang; Kuo-Chen Cheng
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.

Authors:  Zhicheng Jiao; Hongming Li; Ying Xiao; Charu Aggarwal; Maya Galperin-Aizenberg; Daniel Pryma; Charles B Simone; Steven J Feigenberg; Gary D Kao; Yong Fan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-19       Impact factor: 7.038

8.  Characterization of Dyspnea in Veteran Lung Cancer Survivors Following Curative-Intent Therapy.

Authors:  Duc Ha; Andrew L Ries
Journal:  J Cardiopulm Rehabil Prev       Date:  2020-03       Impact factor: 3.646

9.  Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.

Authors:  Christopher J Cadham; Pianpian Cao; Jinani Jayasekera; Kathryn L Taylor; David T Levy; Jihyoun Jeon; Elena B Elkin; Kristie L Foley; Anne Joseph; Chung Yin Kong; Jennifer A Minnix; Nancy A Rigotti; Benjamin A Toll; Steven B Zeliadt; Rafael Meza; Jeanne Mandelblatt
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 11.816

10.  Lung Cancer Stigma Then and Now: Continued Challenges Amid a Landscape of Progress.

Authors:  Heidi A Hamann; Timothy J Williamson; Jamie L Studts; Jamie S Ostroff
Journal:  J Thorac Oncol       Date:  2021-01       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.